- Home
- LAUR vs ACAD Comparison
LAUR vs ACAD Comparison
Compare LAUR & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LAUR
- ACAD
- Stock Information
- Founded
- LAUR 1989
- ACAD 1993
- Country
- LAUR United States
- ACAD United States
- Employees
- LAUR N/A
- ACAD N/A
- Industry
- LAUR Other Consumer Services
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- LAUR Real Estate
- ACAD Health Care
- Exchange
- LAUR Nasdaq
- ACAD Nasdaq
- Market Cap
- LAUR 2.9B
- ACAD 2.5B
- IPO Year
- LAUR 2017
- ACAD 2004
- Fundamental
- Price
- LAUR $22.88
- ACAD $17.44
- Analyst Decision
- LAUR Buy
- ACAD Buy
- Analyst Count
- LAUR 2
- ACAD 15
- Target Price
- LAUR $20.50
- ACAD $24.21
- AVG Volume (30 Days)
- LAUR 799.3K
- ACAD 1.7M
- Earning Date
- LAUR 05-01-2025
- ACAD 05-07-2025
- Dividend Yield
- LAUR N/A
- ACAD N/A
- EPS Growth
- LAUR 143.51
- ACAD N/A
- EPS
- LAUR 1.90
- ACAD 1.37
- Revenue
- LAUR $1,527,432,000.00
- ACAD $996,283,000.00
- Revenue This Year
- LAUR $2.07
- ACAD $13.07
- Revenue Next Year
- LAUR $6.82
- ACAD $10.06
- P/E Ratio
- LAUR $12.09
- ACAD $12.73
- Revenue Growth
- LAUR 1.26
- ACAD 22.42
- 52 Week Low
- LAUR $13.60
- ACAD $13.40
- 52 Week High
- LAUR $23.05
- ACAD $20.68
- Technical
- Relative Strength Index (RSI)
- LAUR 73.62
- ACAD 67.70
- Support Level
- LAUR $19.71
- ACAD $14.45
- Resistance Level
- LAUR $23.06
- ACAD $15.31
- Average True Range (ATR)
- LAUR 0.62
- ACAD 0.69
- MACD
- LAUR 0.34
- ACAD 0.37
- Stochastic Oscillator
- LAUR 95.92
- ACAD 94.92
About LAUR Laureate Education Inc.
Laureate Education Inc is an international community of universities. The company provides higher education programs and services to students through an international network of licensed universities and higher education institutions. Its geographical segments include Peru and Mexico.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.